282 related articles for article (PubMed ID: 29529087)
21. Former Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.
Velink A; Woolley RJ; Phillips RO; Abass KM; van der Werf TS; Agumah E; de Zeeuw J; Klis S; Stienstra Y
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005261. PubMed ID: 28033343
[TBL] [Abstract][Full Text] [Related]
22. Steps Toward Creating A Therapeutic Community for Inpatients Suffering from Chronic Ulcers: Lessons from Allada Buruli Ulcer Treatment Hospital in Benin.
Amoussouhoui AS; Johnson RC; Sopoh GE; Agbo IE; Aoulou P; Houezo JG; Tingbe-Azalou A; Boyer M; Nichter M
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004602. PubMed ID: 27367809
[TBL] [Abstract][Full Text] [Related]
23. Assessment of water, sanitation, and hygiene practices and associated factors in a Buruli ulcer endemic district in Benin (West Africa).
Johnson RC; Boni G; Barogui Y; Sopoh GE; Houndonougbo M; Anagonou E; Agossadou D; Diez G; Boko M
BMC Public Health; 2015 Aug; 15():801. PubMed ID: 26286582
[TBL] [Abstract][Full Text] [Related]
24. Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa.
Wadagni AC; Steinhorst J; Barogui YT; Catraye PM; Gnimavo R; Abass KM; Amofa G; Frimpong M; Sarpong FN; van der Werf TS; Phillips R; Sopoh GE; Johnson CR; Stienstra Y
PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007866. PubMed ID: 31658295
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
[TBL] [Abstract][Full Text] [Related]
26. Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms.
Sopoh GE; Dossou AD; Brun LV; Barogui YT; Houézo JG; Affolabi D; Anagonou SY; Johnson RC; Kestens L; Portaels F
Am J Trop Med Hyg; 2010 Aug; 83(2):307-13. PubMed ID: 20682873
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.
Johnson RC; Sáez-López E; Anagonou ES; Kpoton GG; Ayelo AG; Gnimavo RS; Mignanwande FZ; Houezo JG; Sopoh GE; Addo J; Orford L; Vlasakakis G; Biswas N; Calderon F; Della Pasqua O; Gine-March A; Herrador Z; Mendoza-Losana A; Díez G; Cruz I; Ramón-García S
Trials; 2022 Jul; 23(1):559. PubMed ID: 35804454
[TBL] [Abstract][Full Text] [Related]
28. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin.
Chauty A; Ardant MF; Marsollier L; Pluschke G; Landier J; Adeye A; Goundoté A; Cottin J; Ladikpo T; Ruf T; Ji B
Clin Infect Dis; 2011 Jan; 52(1):94-6. PubMed ID: 21148526
[TBL] [Abstract][Full Text] [Related]
29. Buruli ulcer recurrence, Benin.
Debacker M; Aguiar J; Steunou C; Zinsou C; Meyers WM; Portaels F
Emerg Infect Dis; 2005 Apr; 11(4):584-9. PubMed ID: 15829198
[TBL] [Abstract][Full Text] [Related]
30. [Bifocal Buruli ulcer: multiple cephalic lesions after initiation of medical treatment].
Vagamon B; Ahogo KC; Aka BR; Diabaté A; Kouassi YI; Kourouma SH; Traoré C; Gue I; Yoboue P; Kanga JM; Taieb A
Ann Dermatol Venereol; 2013 Feb; 140(2):125-8. PubMed ID: 23395495
[TBL] [Abstract][Full Text] [Related]
31. In-vitro activity of avermectins against Mycobacterium ulcerans.
Omansen TF; Porter JL; Johnson PD; van der Werf TS; Stienstra Y; Stinear TP
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003549. PubMed ID: 25742173
[TBL] [Abstract][Full Text] [Related]
32. Short report: edematous Mycobacterium ulcerans infection (Buruli ulcer) on the face: a case report.
Phanzu DM; Ablordey A; Imposo DB; Lefevre L; Mahema RL; Suykerbuyk P; Meyers WM; Portaels F
Am J Trop Med Hyg; 2007 Dec; 77(6):1099-102. PubMed ID: 18165530
[TBL] [Abstract][Full Text] [Related]
33. Developing a Buruli ulcer community of practice in Bankim, Cameroon: A model for Buruli ulcer outreach in Africa.
Awah PK; Boock AU; Mou F; Koin JT; Anye EM; Noumen D; Nichter M;
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006238. PubMed ID: 29584724
[TBL] [Abstract][Full Text] [Related]
34. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
[TBL] [Abstract][Full Text] [Related]
35. Findings in patients from Benin with osteomyelitis and polymerase chain reaction-confirmed Mycobacterium ulcerans infection.
Pommelet V; Vincent QB; Ardant MF; Adeye A; Tanase A; Tondeur L; Rega A; Landier J; Marion E; Alcaïs A; Marsollier L; Fontanet A; Chauty A
Clin Infect Dis; 2014 Nov; 59(9):1256-64. PubMed ID: 25048846
[TBL] [Abstract][Full Text] [Related]
36. Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update.
O'Brien DP; Jenkin G; Buntine J; Steffen CM; McDonald A; Horne S; Friedman ND; Athan E; Hughes A; Callan PP; Johnson PD
Med J Aust; 2014 Mar; 200(5):267-70. PubMed ID: 24641151
[TBL] [Abstract][Full Text] [Related]
37. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
[TBL] [Abstract][Full Text] [Related]
38. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions.
Schütte D; Umboock A; Pluschke G
Br J Dermatol; 2009 Feb; 160(2):273-83. PubMed ID: 19016694
[TBL] [Abstract][Full Text] [Related]
39. Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.
Adu EJ; Ampadu E
Int J Mycobacteriol; 2015 Jun; 4(2):138-42. PubMed ID: 26972882
[TBL] [Abstract][Full Text] [Related]
40. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.
Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L
BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
